OVID earnings analysis
What we found in OVID's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ovid’s second-quarter revenue was $733,000, down approximately 87.8% year over year, while diluted EPS was a $0.08 loss and the quarterly net loss was $15.0 million. Liquidity remains the principal positive, with $169.8 million of cash, cash equivalents and marketable securities and management expecting funding for at least 12 months. The company remains pre-commercial, has no approved drugs, expects continued operating losses and provides no numeric revenue or EPS guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined sharply year over year
- Revenue was $733,000, down approximately 87.8% from $6.0 million in the prior-year quarter. The company has no drugs approved for commercialization and has never generated revenue from drug sales.
- Strong liquidity position
- Cash, cash equivalents and marketable securities totaled $169.8 million at June 30, 2026, while management stated this balance should fund operating and capital expenditure requirements for at least 12 months.
- Quarterly EPS improved sequentially
- Diluted EPS was a loss of $0.08. This improved by $0.04 from the prior-quarter loss of $0.12, but deteriorated by $0.02 from the prior-year loss of $0.06.
- Pipeline investment remains substantial
- The quarterly net loss was $15.0 million and accumulated deficit was $353.7 million as of June 30, 2026, underscoring the company’s continued investment and cash-burn profile.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal controls that materially affected, or were reasonably likely to materially affect, financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing losses and financing needs
- The company reported a $15.0 million quarterly net loss and a $353.7 million accumulated deficit. Management expects operating losses to continue and states that additional capital may be needed sooner than planned if operating plans change.
- Tariffs and healthcare policy uncertainty
- The filing highlights heightened macroeconomic and trade-policy exposure, including tariffs that could increase R&D costs and disrupt supply chains. The FDA approved Colorado’s drug-importation proposal on June 15, 2026, adding potential pricing and market-access uncertainty.
- NOL utilization may be restricted
- The filing states that the company completed financings in October 2025 and March 2026 without conducting a formal Section 382 study. It also reports $214.9 million of federal NOL carryforwards, which may be significantly limited and unavailable to offset future taxable income.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and marketable securities of $169.8 million as of June 30, 2026 are expected to fund operating and capital expenditure requirements through at least 12 months from issuance of the interim financial statements.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Ovid Therapeutics reported a total revenue of $0 for Q1 2026, marking a significant decline from the prior year when it generated $130,000. The company's net loss widened to $17 million compared to $10.2 million in Q1…
- 10-K · March 18, 2026
- Ovid positions itself as a small-molecule CNS specialist focused on treating neuronal hyperexcitability with a diversified pipeline (five clinical-stage programs, two advanced to late-stage). Recent clinical readouts…
- 10-Q · November 12, 2025
- Ovid reported Q3 revenue of $132,000 and a net loss per share of $(0.17). Revenue and EPS both missed consensus (revenue $132,000 vs est. $238,228; EPS $(0.17) vs est. $(0.15)), while operating loss narrowed slightly…
- 10-Q · August 13, 2025
- Ovid reported a sharp YoY increase in license revenue to $6.272 million in Q2 2025 (from $169 thousand in Q2 2024) while cutting operating expenses to $11.345 million (from $20.686 million). Despite operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OVID makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever